Listed

LifeMD, Inc.: Form 10-Q for the period ended Jun 30, 2018

Filed with the SEC on Aug 17, 2018 and accepted by EDGAR at Aug 17, 2018, 16:47 ET.

Share

Management's discussion and analysis

As filed, 24,654 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Overview

We are an internet based direct response marketing company that in-licenses, acquires or creates innovative and proprietary products that can be sold to consumers around the world via our technology infrastructure and relationships with agencies, third party marketers, and online advertising platforms such as Facebook and Google. We currently have three commercial stage products and intend to launch an additional two products in 2018. Our leading product, launched in the second quarter of 2017, is a patented shampoo, conditioner, and leave-in foamer for thicker, fuller hair. Our second product, launched in the first quarter of 2018, is a nutritional supplement for immune support. Our third product, launched in the second quarter of 2018, is a PDF conversion software, which was acquired through the purchase of 51% of the membership interests of LegalSimpli Software, LLC, a Puerto Rico limited liability company, which operates a marketing-driven software solutions business.

We launched our online direct marketing business in the fourth quarter of 2015 with the establishment of a partnership with Inate Skincare, LLC (“Inate”). Our initial intention was to launch a skin care line containing our proprietary ingredients and to market such products directly to consumers. The Company entered into a limited liability company operating agreement with its joint venture partners with respect to Inate under the legal name Immudyne PR LLC (“Immudyne PR”). On April 1, 2016, the original operating agreement of Immudyne PR was amended and restated and we increased our ownership and voting interest in Immudyne PR to 78.16667%.

During our fiscal year ended December 31, 2017, we manufactured, distributed and sold natural immune support products; namely proprietary yeast beta glucans which are natural extracts that have been shown through testing and analysis and scientific research to support the immune system. Yeast beta glucans are classified as generally recognized as safe (“GRAS”) by the Food and Drug Administration (“FDA”). We are and have been a science driven company for more than 25 years. Our products are used in oral and topical applications. Historically, we have sold our proprietary additives, for both oral and topical use, primarily via business-to-business to large dietary supplement and cosmetic companies.

Our priority is to pursue opportunities to market our products and increase sales. We expect that a significant component of our selling, general and administration expenses going forward will consist of service fees to maintain skilled professionals to market our products online, as well as conducting analysis on market trends and dynamically change our approach to drive sales. These aforementioned costs, along with the additional costs resulting from our operations as a public reporting company, could adversely impact our future results of operations. Additional significant factors that we believe will affect our operating results going forward are: (i) protection of our intellectual property rights; (ii) imposition of more stringent government regulations of our products; and (iii) direct marketing expenses.

In the 2016 fiscal year, we utilized third party entities to provide and increase credit card processing capacity and optimize corresponding rates and fees through one or more merchant bank accounts held by such entities. A majority of these entities providing these services were consolidated as VIEs which received a one (1%) percent fee eliminated in consolidation of the net revenues processed and collected by such contractors from sales initiated by the Company. The remaining entities provided such services as independent contractors, the majority of which were considered related parties and no fee was paid. Upon receipt of funds by such contractors from their respective merchant banks, the Company required the prompt transfer of funds to Company controlled accounts. The Company reimbursed and/or advanced funds to such contractors for any deficit or charge related to returns, chargeback and other fees charged by such merchant bank. Some of the entities contracted to provide these services have been determined to be variable interest entities and consolidated in the Company’s financial statements. By our fiscal year ending December 31, 2017, we ceased processing credit card charges through all VIE merchant accounts. At December 31, 2017, we recorded the merchant reserves from these VIE merchant accounts on our balance sheet as Accounts Receivable.

We historically have expended a significant amount of our funds on obtaining and protecting our patents, trade secrets and proprietary products. We rely on the patent and trademark protection laws in the U.S. to protect our intellectual property and maintain our competitive position in the marketplace.

We have historically operated with limited capital and have funded operations in the past through the sales of our products and loans and advances from our past executives and directors. Late in the 2016 fiscal year and early in 2017, the Company issued several 11% subordinated promissory notes to accredited investors for total borrowings of $200,000, which have been satisfied in 2016 and 2017. In late 2017, we obtained $125,000 in promissory notes from our executive officers for the Immudyne PR entity, which were satisfied in early 2018. We plan on our operating business (in conjunction with proceeds from debt and equity financings completed in 2016 and early 2017) to be able to fund operations through 2018. However, in the event we require additional operating capital we may have to depend on sources other than operating revenues to meet our operating and capital needs. No assurance can be given that such sources will be available, and no assurance can be given that our executive officers or other directors who have, in the past, willingly funded operations will commit to do so in the future, or that we will be successful in our endeavors to raise additional capital. For additional information regarding these and other risks please see “Risk Factors” contained in our annual report for the fiscal year ended December 31, 2017.

Divestiture of Nutraceutical and Cosmetic Additives Business

Throughout 2017, we manufactured, distributed and sold natural immune support products containing our proprietary yeast beta glucans, a group of beta glucans naturally occurring in the cell walls of yeast that have been shown through testing and analysis to support the immune system. Beta glucans, or β-Glucans, are a natural extract that are considered to be “biological response modifiers” that support the immune system. The most common sources of beta glucans are from the cell walls of baker’s yeast, the cellulose in plants, the bran of cereal grains and certain fungi and bacteria.

In 2017, our yeast beta glucan nutraceutical and cosmetic product lines consisted of our natural, premium yeast beta glucans in oral and topical applications. We offered our yeast beta glucans as natural raw material ingredients in bulk quantities under our “Nutraceutical and Cosmetic Additives” segment, and finished, consumer products packaged under our brands as well as private label brands under our “Finished Cosmetic Products” segment, which were marketed directly to consumers.

In the first quarter of 2018 we sold assets and certain liabilities related to our legacy business that manufactured raw yeast beta glucan. As a result of this divestiture, we now solely operate our online direct marketing business owned by Immudyne PR.

Acquisition of Membership Interest Purchase Agreement

On May 29, 2018, Immudyne, PR acquired 51% of the membership interests (the “Membership Interests”) of LegalSimpli Software, LLC, a Puerto Rico limited liability company (“LSS”), which operates a marketing-driven software solutions business.

In consideration for Buyer’s purchase of the Membership Interests the Buyer paid $150,000 (the “Initial Payment”) to the Sellers upon execution of the Purchase Agreement. Additionally, Buyer may be obligated to pay up to an additional $200,000 in accordance with the following milestones (the “Milestones”): (i) $100,000 to the Sellers on the 90-day anniversary of the Purchase Agreement, so long LSS’s gross revenue for the preceding 30-day period is equal to or greater than $75,000; and (ii) $100,000 to the Sellers on the 180-day anniversary of the Purchase Agreement, so long as LSS’s gross revenue for the preceding 30-day period is equal to or greater than $150,000, with a minimum net profit margin of 25% in each instance.

Regardless of whether LSS achieves either or both of the Milestones, Buyer will retain full ownership of the Membership Interests.

Results of Operations

Three Months Ended June 30, 2018, compared to the Three Months Ended June 30, 2017

The following table sets forth the results of our current operations for the three month periods indicated as a percentage of net sales:

Three Months Ended June 30, 2018 $% of Sales Three Months Ended June 30, 2017 $% of Sales
Net Sales 2,037,636 660,087
Cost of sales 534,727 15% 185,098 22%
Gross profit 1,502,909 41% 474,989 57%
Operating expenses 2,100,402 58% 855,291 103%
Operating (Loss) (597,493) (16)% (380,302) (46)%
Change in fair value of derivative liability - -% 922,022 111%
Interest (expense) (51,078) (1)% (250) -%
Loss from continuing operations (648,571) (18)% 541,470 65%
Income from discontinued operations, including gain on sale, net of income taxes - -% 154,825 19%
Net income (loss) (648,571) (18)% 696,295 84%
Net Income (loss) attributable to noncontrolling interests (41,539) (1)% (41,194) (5)%
Net Income (loss) attributable to Conversion Labs, Inc. (607,032) (17)% 737,489 89%

27

Net Sales

Sales were approximately $2.04 million for the three months ended June 30, 2018, compared to approximately $660,000 for the three months ended June 30, 2017. The increase of approximately 209% is attributed mainly to more resources being invested into our in-licensed patented hair loss shampoo, conditioner, and leave in foam during the second quarter of 2018.

Cost of Sales

Total cost of sales was approximately $535,000 for the three months ended June 30, 2018, compared to approximately $185,000 for the three months ended June 30, 2017. The increase in our cost of sales was mainly due to increased sales as of our in-licensed patented hair loss shampoo, conditioner, and leave in foam during the second quarter of 2018. Cost of sales consists primarily of material costs and related overhead directly attributable to the production of our products. Cost of Sales as a percentage of income decreased as we were able to take advantage of volume pricing discounts from our vendors.

Gross Profit

Gross profit was approximately $1.50 million for the three months ended June 30, 2018, compared to approximately $475,000 for the three months ended June 30, 2017, an increase of approximately 216%. The increase in our gross profit was a result of the increased sales of our in-licensed patented hair loss shampoo, conditioner and leave-in foam.

Operating Expenses

Total operating expenses increased approximately 146% to approximately $2.10 million for the three months ended June 30, 2018, from approximately $855,000 for the three months ended June 30, 2017. The increase in our operating expenses between the periods was mostly attributable to our increased marketing efforts for our in-licensed patented hair loss shampoo, conditioner and leave-in foam, which increased approximately $982,000 over from the three-months ended June 30, 2018 compared to the three-months ended June 30, 2017. We also had increased compensation expenses and professional fees, however lower general and administrative costs during the comparable period.

Net Income

Net loss from continuing operations for the three months ended June 30, 2018 was approximately $649,000, compared to net income from continuing operations of approximately $541,000 for the three months ended June 30, 2017. Our net loss from continuing operations for the three months ended June 30, 2018 was mostly attributable to our increased marketing efforts, whereas our net income from continuing operations for the three months ended June 30, 2017 was mostly attributable to the change in fair value of derivative liability, offset by mostly general and administrative expenses as we incurred costs of while launching the online marketing of products. As a result of the sale of our Nutraceutical and Cosmetic Additives business, we recorded net income from discontinued operations of approximately $649,000 for the three months ended June 30, 2018 versus net income from discontinued operations of approximately $696,000 for the three months ended June 30, 2017. We consolidated the operations of our joint venture, Immudyne PR and reflected a non-controlling interest for 21.8333% of these operations. Net loss attributable to the Company as a percentage of sales was approximately 17% for the three months ended June 30, 2018, compared to net income as a percentage of sales of approximately 89% for the three months ended June 30, 2017. Our net loss during the period was mostly attributable to the increasing in marketing efforts.

Results of Operations

Six Months Ended June 30, 2018, compared to the Six Months Ended June 30, 2017

The following table sets forth the results of our current operations for the six- month periods indicated as a percentage of net sales:

Six Months Ended June 30, 2018 $% of Sales Six Months Ended June 30, 2017 $% of Sales
Net Sales 3,644,127 827,986
Cost of sales 890,180 24% 273,271 33%
Gross profit 2,753,947 76% 554,715 67%
Operating expenses (3,630,754) (100)% (1,336,810) (161)%
Operating (Loss) (876,807) (24)% (782,095) (94)%
Change in fair value of derivative liability - -% 873,830 106%
Interest (expense) (57,528) (2)% (649,607) (78)%
Loss from continuing operations (934,335) (26)% (557,872) (67)%
Income from discontinued operations, including gain on sale, net of income taxes 925,738 25% 181,632 22%
Net income (loss) (8,597) -% (376,240) (45)%
Net Income (loss) attributable to noncontrolling interests -28,842 (1)% (68,924) (8)%
Net Income (loss) attributable to Conversion Labs, Inc. 20,245 1% (307,316) (37)%

Net Sales

Sales were approximately $3.6 million for the six months ended June 30, 2018, compared to approximately $828,000 for the six months ended June 30, 2017. The increase of approximately 340% is attributed to more resources allocated to our in-licensed patented hair loss shampoo, conditioner, and leave in foam during the first half of 2018.

Cost of Sales

Total cost of sales was approximately $890,000 for the six months ended June 30, 2018, compared to $273,000 for the three months ended June 30, 2017. The increase in our cost of sales was due to increased sales from our in-licensed patented hair loss shampoo, conditioner, and leave in foam during the first half of 2018. Cost of sales consists primarily of material costs and related overhead directly attributable to the production of our products. Cost of Sales as a percentage of income decreased as we were able to take advantage of volume pricing discounts from our vendors.

Gross Profit

Gross profit was approximately $2.75 million for the six months ended June 30, 2018, compared to approximately $555,000 for the six months ended June 30, 2018, an increase of approximately 396%. The increase in our gross profit was a result of the increased sales of our in-licensed patented hair loss shampoo, conditioner and leave-in foam.

Operating Expenses

Total operating expenses increased approximately 172% to approximately $3.63 million for the six months ended June 30, 2018, from approximately $1.34 million for the six months ended June 30, 2017. The increase in our operating expenses between the periods was mostly attributable to our increased marketing efforts for our in-licensed patented hair loss shampoo, conditioner and leave-in foam.

Net Income

Net loss from continuing operations for the six months ended June 30, 2018 was approximately $934,000, compared to net loss from continuing operations of approximately $558,000 for the six months ended June 30, 2017. Our net loss from continuing operations for the six months ended June 30, 2018 was mostly attributable to our increased marketing efforts, whereas our net loss from continuing operations for the six months ended June 30, 2017 was mostly attributable to general and administrative and compensation expenses as we incurred costs of building resources and hiring employees prior to launching the online marketing of products. As a result of the sale of our Nutraceutical and Cosmetic Additives business, we recorded net income from discontinued operations of approximately $926,000 for the six months ended June 30, 2018 versus net income from discontinued operations of approximately $182,000 for the six months ended June 30, 2017. We consolidated the operations of our joint venture, Immudyne PR and reflected a non-controlling interest for 21.8333% of these operations. Net income attributable to the Company as a percentage of sales was approximately 1% for the six months ended June 30, 2018, compared to net loss as a percentage of sales of approximately 37% for the six months ended June 30, 2017. Our net income during the period was attributable to the gain recorded on the sale of our Nutraceutical and Cosmetic Additives business, which offset increasing in marketing efforts.

Liquidity and Capital Resources

Our principal demands for liquidity are to increase sales via online marketing, purchase inventory and for sales distribution and general corporate purposes. We incurred negative operating cash flows of our continued operations to date in 2018 as well as in the 2017 fiscal year. As a result, we have substantial doubt about our ability to continue as a going concern. In early in 2017, the Company issued several 11% subordinated promissory notes to accredited investors for total borrowings of $200,000. Additionally, the Company borrowed $200,000 at 11% from an investor and borrowed $100,000 from an officer of the Company. In late 2017, the Company borrowed $125,000 from its executives. Each of these borrowings have since been satisfied in full with a combination of repayment in cash and conversion of certain amounts outstanding to equity of the Company.

In our fiscal year 2017, the Company issued and sold 2,927,156 shares and 1,414,078 warrants to accredited investors in an offering pursuant to Regulation D and received proceeds in the amount of $673,245. We do not plan on our operating business (in conjunction with proceeds from debt and equity financings completed in 2017) being able to fund operations through 2018. After the sale of our legacy Nutraceutical and Cosmetic Additives business the Company loaned Immudyne PR LLC $100,000 to fund its operations because of increased marketing activity. In March 2018, the Company began seeking additional debt and equity financing to raise capital for its continued operations, and in May 2018, the Company borrowed $550,000 and issued convertible notes payable with a maturity date of May 28, 2019 in connection therewith. These notes accrue interest at a rate of 12% compounded annually. The conversion price for these notes is $0.23 per share of common stock, subject to adjustment. In the event the average VWAP (as defined) for the consecutive five trading days preceding but not including the six month anniversary of the original issue date of the note is less than the then conversion price in effect on such six month anniversary date, then the conversion price shall be reduced to 80% of the VWAP for the ten trading days following (but not including) such six month anniversary date, subject to further reduction. In addition, in connection with this May financing the Company issued warrants to purchase up to 2,391,305 shares of common stock at a price of $0.28 per share. Even after the May 2018 financing, the Company may need to raise more capital to fund its operations.

There can be no assurance that required future financing can be successfully completed on a timely basis, or on terms acceptable to us. Any future issuance of equity securities could cause dilution to our shareholders. Any incurrence of indebtedness would increase our debt service obligations and would cause us to be subject to restrictive operating and financial covenants.

We had positive net working capital of $959,898 at June 30, 2018, resulting in an increase in working capital from net working capital of $622,839 at December 31, 2017. The ratio of current assets to current liabilities was 2.88 to 1 at June 30, 2018.

The following is a summary of cash provided by or used in each of the indicated types of activities during the three months ended June 30, 2018 and 2017:

Cash provided by (used in): 2018 2017
Operating activities of continuing operations $(228,176) (512,569)
Investing activities 241,445 -
Financing activities 536,521 766,094

Net cash used by operating activities of continuing operations was $228,176 for the six months ended March 31, 2018, compared to net cash used in operating activities of continuing operations of $512,569 for the same period in 2017. The decrease in the amount of cash used by our operating activities was due primarily our ability to generate more cash from higher sales of product from our online marketing business run out of Immudyne PR LLC.

Net cash flows used in financing activities was $536,521 for the six months ended June 30, 2018, compared to net cash flows provided by financing activities of $766,094 for the same period in 2017. Our decrease in net cash flows provided by financing activities was primarily a result of the sale of our common stock and warrants, and proceeds from notes payable in the first quarter of 2017, in addition to the repayment of notes payable to executives in the first quarter of 2018.

Indebtedness

From time to time, our directors, officers and other related individuals have made short-term advances to us for our operating needs. Early in 2017, the Company issued several 11% subordinated promissory notes to accredited investors for total borrowings of $200,000, borrowed $200,000 at 11% from an investor and borrowed $100,000 from an officer of the Company. In late 2017, the Company borrowed $125,000 from its executives. Each of these borrowings have since been satisfied in full with a combination of repayment in cash and conversion of certain amounts outstanding to equity of the Company.

Off-Balance Sheet Arrangements

On November 20, 2017, the Company entered into an agreement (the “Agreement”) with JOJ Holdings, LLC (“JOJ”). Pursuant to the terms of the Agreement, the Company purchased 2,000,000 shares (post-split from a 2:1 forward split on January 16, 2018) of Blockchain Industries, Inc. (“BCII”) from JOJ. The Agreement was amended on December 8, 2017 and again on March 9, 2018. In consideration for the purchase, the Company agreed to issue one (1) share of its common stock to JOJ for every dollar the Company realizes from gross proceeds on the sale of shares of BCII purchased pursuant to the Agreement, up to a total maximum aggregate amount of 5,000,000 shares. The Company has 3 years to sell the shares of BCII and has agreed not to sell more than 20% of the 30-day average daily trading volume of BCII. Justin Schreiber, the Company’s President and CEO, is the President and owner of JOJ. The initial assessment of this transaction was determined not to meet the basis of an exchange transaction per ASC 845-10-20. The Company will reassess the off-balance sheet arrangement at each reporting period to determine the any change in the accounting as an off-balance sheet arrangement.

Critical Accounting Policies

Our significant accounting policies are described more fully in Note 2 of our Form 10-K filed April 2, 2018, which we believe are the most critical to aid you in fully understanding and evaluating this management discussion and analysis.

Market risk

As filed, 182 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There has been no default in the payment of principal, interest, sinking or purchase fund installment, or any other material default, with respect to any indebtedness of the Company.

Controls and procedures

As filed, 2,663 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our Principal Executive Officer (“PEO”), and our Principal Financial Officer (“PFO”), of the design and effectiveness of our “disclosure controls and procedures” (as defined under Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered by this report. Based on this evaluation, our PEO/PFO concluded that as of the end of the period covered by this report, these disclosure controls and procedures were not effective for the Company or our majority owned subsidiaries Immudyne PR and LegalSimpli. The conclusion that our disclosure controls and procedures were not effective was due to the presence of the following material weaknesses in disclosure controls and procedures which are indicative of many small companies with small staff: (i) inadequate segregation of duties and effective risk assessment as the Company’s officers did not have ample time to prepare sufficient risk assessments for the reporting period; (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC Guidelines; (iii) inadequate security and restricted access to computer systems including insufficient disaster recovery plans; and (iv) no written whistleblower policy.

Our PEO and PFO intend to implement appropriate disclosure controls and procedures to remediate these material weaknesses. During 2018, we expect more internal controls, financial and operational, to be implemented, especially around inventory and operational controls, which management has identified as a material control deficiency.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the six-month period ended June 30, 2018, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Risk factors

As filed, 216 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We believe there are no changes that constitute material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on April 2, 2018.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2018-04-01 to 2018-06-30$2.0mus-gaap:Revenues
Revenue6 months2018-01-01 to 2018-06-30$3.6mus-gaap:Revenues
Cost of revenue3 months2018-04-01 to 2018-06-30$534.7kus-gaap:CostOfRevenue
Cost of revenue6 months2018-01-01 to 2018-06-30$890.2kus-gaap:CostOfRevenue
Gross profit3 months2018-04-01 to 2018-06-30$1.5mus-gaap:GrossProfit
Gross profit6 months2018-01-01 to 2018-06-30$2.8mus-gaap:GrossProfit
Operating income3 months2018-04-01 to 2018-06-30−$597.5kus-gaap:OperatingIncomeLoss
Operating income6 months2018-01-01 to 2018-06-30−$876.8kus-gaap:OperatingIncomeLoss
Interest expense3 months2018-04-01 to 2018-06-30$51.1kus-gaap:InterestExpense
Interest expense6 months2018-01-01 to 2018-06-30$57.5kus-gaap:InterestExpense
Net income3 months2018-04-01 to 2018-06-30−$607.0kus-gaap:NetIncomeLoss
Net income6 months2018-01-01 to 2018-06-30$20.2kus-gaap:NetIncomeLoss
Diluted shares (weighted)3 months2018-04-01 to 2018-06-3045,289,027 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2018-01-01 to 2018-06-3045,458,780 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2018-01-01 to 2018-06-30−$228.2kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2018-06-30$691.2kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-06-30$1.5mus-gaap:AssetsCurrent
Total assetsAt period end2018-06-30$1.8mus-gaap:Assets
Current liabilitiesAt period end2018-06-30$511.5kus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2018-06-30$1.3mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001213900-18-011363. Last ingested by Listed: Nov 13, 2026, 16:33 ET. Listed shows no prices and gives no investment advice.